Pins matching tag:Amgen

On 1 June 1989 the FDA approved Epogen (epoetin alfa), Amgen's recombinant erythropoietin for anemia in kidney dialysis patients, its first product after nine years in business.

On 6 October 2023 Amgen completed its acquisition of Horizon Therapeutics for US$116.50 per share in cash, a transaction equity value of about US$27.8 billion that added Tepezza, Krystexxa and Uplizna.

On 26 November 2024 Amgen reported 52-week Phase 2 data for its monthly obesity candidate MariTide, with up to about 20% average weight loss without a plateau, and announced the MARITIME Phase 3 program.

On 27 April 2026 the FDA's drug centre issued a proposal to withdraw approval of Amgen's Tavneos for ANCA-associated vasculitis, alleging lack of substantial evidence of effectiveness; Amgen disagrees and the drug stays on the market.

On 4 August 2026 Amgen reported second-quarter revenue up 10% to US$10.1 billion, with GAAP EPS of US$4.37 and non-GAAP EPS of US$6.29, as 22 products grew at double-digit rates.